Sex Differences in Dopamine Receptor Signaling in Fmr1 Knockout Mice: A Pilot Study

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Fragile X syndrome (FXS) is an X-linked genetic disorder causing cognitive and developmental issues.
• Current FXS treatments are symptomatic, lacking targeted therapies for the underlying cause.
• FXS exhibits sex-specific manifestations, including dopamine system abnormalities, observed in Fmr1-knockout (KO) mouse models.

Purpose of the Study:

• To investigate sex differences in dopamine signaling pathways in Fmr1-KO mice.
• To examine the effects of L-stepholidine, a dopamine receptor agonist/antagonist, on these pathways.
• To identify potential sex-specific therapeutic targets for FXS.

Main Methods:

• Utilized Fmr1-KO mice and wild-type littermates.
• Administered L-stepholidine, a dopamine D1 receptor agonist and D2 receptor antagonist.
• Measured basal and drug-induced levels of phosphorylated protein kinase A (p-PKA) and glycogen synthase kinase (GSK)-3β.

Main Results:

• Wild-type mice showed sex differences in basal p-PKA and p-GSK-3β, absent in Fmr1-KO mice.
• L-stepholidine differentially affected p-PKA and p-GSK-3β in male and female wild-type mice.
• In Fmr1-KO mice, L-stepholidine increased p-PKA and p-GSK-3β in females, while decreasing them in males.

Conclusions:

• FXS is associated with sex-specific alterations in dopamine signaling pathways.
• L-stepholidine's effects on key signaling molecules are sex-dependent in both wild-type and Fmr1-KO mice.
• These findings highlight potential sex-specific therapeutic strategies for Fragile X syndrome.